Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from GMAB

Why Is Genmab Stock Trading Lower On Monday?

On Saturday, Genmab A/S (NASDAQ:GMAB) revealed updated data from cohort B2 of the Phase 1/2 RAINFOL-01 trial evaluating rinatabart sesutecan (Rina-S) in heavily pretreated patients with advanced endometrial cancer.

Genmab Makes $8 Billion Bet On Merus With Potential Cancer Breakthrough

Genmab Makes $8 Billion Bet On Merus With Potential Cancer Breakthrough

Genmab A/S (NASDAQ: GMAB) on Monday agreed to acquire Merus N.V. (NASDAQ: MRUS) with its late-stage asset petosemtamab, which is in Phase 3 development, for $97 per share in an all-cash transaction representing a transaction value of approximately $8 billion.

Genmab/AbbVie Partnered Blood Cancer Combination Drug Cuts Risk Of Disease Progression By 79%

Genmab/AbbVie Partnered Blood Cancer Combination Drug Cuts Risk Of Disease Progression By 79%

Genmab A/S (NASDAQ:GMAB) released results Thursday of the Phase 3 EPCORE FL-1 trial evaluating subcutaneous epcoritamab in combination with rituximab and lenalidomide (R2) versus R2 alone for adult patients with relapsed or refractory (R/R) follicular lymphoma (FL).

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

3 Biotech Stocks Gaining Altitude and Interest

This year, the biotech industry anticipates a resurgence with increased M&A, FDA approvals, and AI-driven innovations. Given the industry’s rosy prospects, biotech stocks BioMarin Pharmaceutical (BMRN), ANI Pharmaceuticals (ANIP), and Genmab A/S (GMAB), gaining significant altitude and interest, could be ideal buys. Read on.

Top Biotech 3 Stocks With Accelerating Profits

The biotechnology industry is booming thanks to growing demand for innovative healthcare solutions, favorable government initiatives, and several scientific breakthroughs. Thus, quality biotech stocks Genmab (GMAB), Halozyme Therapeutics (HALO), and Vertex Pharmaceuticals (VRTX) could be ideal buys for substantial profits. Read more….

Bank on the Future Returns With These 3 Biotech Stocks

With advances in gene therapy and personalized medicine, growing applications in agriculture and industrial processes, government support, and convergence of technologies, the biotechnology industry holds solid growth potential. Thus, biotech stocks United Therapeutics (UTHR), Puma Biotechnology (PBYI), and Genmab (GMAB) could be ideal investments for future returns. Read more….

This Week's Biotech Stock Star Performers

The biotech industry is poised for robust growth thanks to the increasing demand for personalized treatments, the rise in chronic diseases, a rapidly aging population, the adoption of advanced technologies, and government initiatives. Therefore, to capitalize on the industry’s growth prospects, one could consider buying fundamentally strong biotech stocks Genmab…

inkl

Read news from The Economist, FT, and more,
with one subscription

Are These 3 Biotech Stocks Poised for 2024 Growth?

Are These 3 Biotech Stocks Poised for 2024 Growth?

The biotech industry is well-positioned for solid growth thanks to the increasing demand for effective treatments for chronic diseases, a rapidly aging population, the adoption of technologies like AI, and government initiatives. To capitalize on the biotech industry’s growth prospects, should one consider investing in biotech stocks Puma Biotechnology (PBYI),…

3 Biotech Stocks to Boost Portfolios

3 Biotech Stocks to Boost Portfolios

The biotech sector, fueled by genetic breakthroughs and digital innovations, is witnessing unprecedented growth. Hence, fundamentally sound biotech stocks Genmab (GMAB), Jazz Pharmaceuticals (JAZZ), and Exelixis (EXEL) might give a solid boost to one’s portfolio. Keep reading.

3 Solid Biotech Buys for a Healthy Year-End Portfolio

3 Solid Biotech Buys for a Healthy Year-End Portfolio

The growing adoption of AI technologies by biopharmaceutical companies and the increasing government initiatives worldwide are expected to boost the biotech industry. Therefore, it could be wise to buy fundamentally strong biotech stocks Innoviva (INVA), Genmab (GMAB), and Alnylam Pharmaceuticals (ALNY) for a healthy year-end portfolio. Read more.

3 Biotech Stocks Bursting With Investment Potential

3 Biotech Stocks Bursting With Investment Potential

The biotech industry is well-positioned for robust growth thanks to the increasing demand for effective treatments for chronic diseases and the need to serve an aging population. To capitalize on the favorable industry trends, investing in quality biotech stocks Organogenesis Holdings (ORGO), Genmab A/S (GMAB), and Incyte (INCY) could be…

3 Biotech Stocks to Watch in November

3 Biotech Stocks to Watch in November

The biotech industry’s expansion stems from advancements in bio-medical drug development and cutting-edge technology. Given these factors, prominent biotech stocks Inovio Pharmaceuticals (INO), Surrozen (SRZN), and Genmab A/S (GMAB) could be solid watchlist additions now. Read on….

Invest in These 3 High-Growth Biotech Stocks

Invest in These 3 High-Growth Biotech Stocks

Technological improvements, government, and private investment, and favorable regulatory policies are propelling the biotech industry’s growth and offering breakthrough cures and products. With the industry expected to thrive, fundamentally strong biotech stocks Genmab (GMAB), Incyte (INCY), and LAVA Therapeutics (LVTX) look poised for solid growth. Hence, these stocks could be…

3 Value Stocks With Investment Opportunities

3 Value Stocks With Investment Opportunities

Amid rising concerns about an economic slump, strong fundamentals of value stocks Genmab A/S (GMAB), International Consolidated Airlines Group (ICAGY), and InterDigital (IDCC) could make them solid buys now. Read on….

Get all your
news in one place.

100’s of premium titles.
One news app.

2 Explosive Biotech Stocks to Own

The biotech industry is well-positioned to grow, thanks to breakthrough advances, rising chronic illness and government support. So, fundamentally solid biotech stocks, Genmab (GMAB) and Exelixis (EXEL) may be worth buying now. Read on.

AbbVie - Genmab Present Epcoritamab Data From Lymphoma Trial

AbbVie Inc (NYSE:ABBV) announced primary results from the large B-cell lymphoma (LBCL) expansion cohort in the EPCORE NHL-1 phase 2 trial of epcoritamab. Epcoritamab demonstrated efficacy with durable responses in patients who had previously received at least two prior lines of anti-lymphoma therapy. The study cohort, which included 157 relapsed/refractory LBCL patients, demonstrated…

AbbVie - Genmab Post Epcoritamab Data From Early-Stage Blood Cancer Study

Genmab A/S (NASDAQ: GMAB) and AbbVie Inc (NYSE: ABBV)

Janssen Partner Genmab Loses Arbitration Over Darzalex Royalties

Johnson & Johnson's (NYSE:JNJ) Janssen has won an arbitration against Genmab A/S (NASDAQ:GMAB) on two matters related to their licensing pact for multiple myeloma drug Darzalex (daratumumab). The first issue around daratumumab arose because Janssen announced a deal with Halozyme Therapeutics Inc (NASDAQ: HALO) to develop a subcutaneous formulation of daratumumab. According to Janssen, Genmab must share…

Get all your
news in one place.

100’s of premium titles.
One news app.

People

Kritika SarmahHer

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

US Federal Reserve

Gilead Sciences Inc

Vertex Pharmaceuticals Incorporated

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Endometrial Cancer

Places

345,343 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play